UK markets close in 4 hours 36 minutes

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
893.99-7.20 (-0.80%)
At close: 04:00PM EDT
925.25 +31.26 (+3.50%)
After hours: 05:43PM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
3,953,600
3,953,600
4,338,400
8,075,300
3,513,200
Depreciation & amortisation
421,000
421,000
341,400
286,200
235,900
Deferred income taxes
-837,800
-837,800
-746,400
-147,100
75,600
Stock-based compensation
885,000
885,000
725,000
601,700
432,000
Change in working capital
-94,100
-94,100
-243,300
-1,916,500
-1,503,600
Accounts receivable
-338,800
-338,800
707,800
-1,927,400
-1,356,100
Inventory
-271,700
-271,700
-696,500
-494,300
-529,400
Accounts payable
598,600
598,600
-138,400
866,100
118,900
Other working capital
3,667,600
3,667,600
3,398,000
6,529,400
2,003,500
Other non-cash items
-100
-100
563,000
568,700
86,800
Net cash provided by operating activities
4,594,000
4,594,000
5,014,900
7,081,300
2,618,100
Cash flows from investing activities
Investments in property, plant and equipment
-926,400
-926,400
-1,616,900
-551,900
-614,600
Acquisitions, net
-54,900
-54,900
-230,300
0
-
Purchases of investments
-11,646,000
-11,646,000
-7,487,900
-7,048,100
-3,241,000
Sales/maturities of investments
9,442,200
9,442,200
5,550,500
2,215,300
3,785,000
Other investing activities
-
-
-230,300
-
-
Net cash used for investing activities
-3,185,100
-3,185,100
-3,784,600
-5,384,700
-70,600
Cash flows from financing activities
Debt repayment
-
-
0
0
-1,500,000
Common stock issued
1,145,500
1,145,500
1,519,500
1,672,300
2,575,200
Common stock repurchased
-2,935,600
-2,935,600
-2,528,500
-2,678,100
-6,527,600
Net cash used provided by (used for) financing activities
-1,790,100
-1,790,100
-1,009,000
-1,005,800
-1,970,500
Net change in cash
-381,600
-381,600
221,300
690,800
577,000
Cash at beginning of period
3,119,400
3,119,400
2,898,100
2,207,300
1,630,300
Cash at end of period
2,737,800
2,737,800
3,119,400
2,898,100
2,207,300
Free cash flow
Operating cash flow
4,594,000
4,594,000
5,014,900
7,081,300
2,618,100
Capital expenditure
-926,400
-926,400
-1,616,900
-551,900
-614,600
Free cash flow
3,667,600
3,667,600
3,398,000
6,529,400
2,003,500